ArticleAddictive behaviors2015
Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
Article in Addictive behaviors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020Pooled it
- A trial of implementation facilitation to increase timely admission to methadone treatment.Journal of substance use and addiction treatment · 2024Trial
- Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont.Preventive medicine · 2021Trial
- Patient-centered methadone treatment: a randomized clinical trial.Addiction (Abingdon, England) · 2017Trial
- Interim Buprenorphine vs. Waiting List for Opioid Dependence.The New England journal of medicine · 2016Trial
- Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.JAMA network open · 2023Article
- A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder.Frontiers in psychiatry · 2023Article
- Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.Journal of substance abuse treatment · 2022Article
- Challenges and opportunities during the COVID-19 pandemic: Treating patients for substance use disorders during the perinatal period.Preventive medicine · 2021Article
- Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.Pain medicine (Malden, Mass.) · 2021Article
- Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.Drug and alcohol dependence · 2020Article
- Potential uses of naltrexone in emergency department patients with opioid use disorder.Clinical toxicology (Philadelphia, Pa.) · 2019Review
- A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.Contemporary clinical trials · 2019Article
- Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review.JMIR mental health · 2019Article
- Development of a Cascade of Care for responding to the opioid epidemic.The American journal of drug and alcohol abuse · 2019Article
- Combining ecological momentary assessment with objective, ambulatory measures of behavior and physiology in substance-use research.Addictive behaviors · 2018Review
- Estimating State Transitions for Opioid Use Disorders.Medical decision making : an international journal of the Society for Medical Decision Making · 2017Article
- Update on Barriers to Pharmacotherapy for Opioid Use Disorders.Current psychiatry reports · 2017Review
- Editorial: 2nd Special Issue on behavior change, health, and health disparities.Preventive medicine · 2015Article
- Interim treatment: Bridging delays to opioid treatment access.Preventive medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Despite the effectiveness of agonist maintenance for opioid dependence, individuals can remain on waitlists for months, during which they are at significant risk for morbidity and mortality. Interim dosing, consisting of daily medication without counseling, can reduce these risks. In this pilot study, we examined the initial feasibility of a novel technology-assisted interim buprenorphine treatment for waitlisted opioid-dependent adults. Following buprenorphine induction during Week 1, participants (n=10) visited the clinic at Weeks 2, 4, 6, 8, 10 and 12 to ingest their medication under staff observation, provide a urine specimen and receive their remaining doses via a computerized Med-O-Wheel Secure device. They also received daily monitoring via an Interactive Voice Response (IVR) platform, as well as random call-backs for urinalysis and medication adherence checks. The primary outcome was percent of participants negative for illicit opioids at each 2-week visit, with secondary outcomes of past-month drug use, adherence and acceptability. Participants achieved high levels of illicit opioid abstinence, with 90% abstinent at the Week 2 and 4 visits and 60% at Week 12. Significant reductions were observed in self-reported past-month illicit opioid use (p<.001), opioid withdrawal (p<.001), opioid craving (p<.001) and ASI Drug composite score (p=.008). Finally, adherence with buprenorphine administration (99%), daily IVR calls (97%) and random call-backs (82%) was high. Interim buprenorphine treatment shows promise for reducing patient and societal risks during delays to conventional treatment. A larger-scale, randomized clinical trial is underway to more rigorously examine the efficacy of this treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.